Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.

Royalty Pharma (RPRX) announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s (RHHBY) Evrysdi for $240M ...

Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today ...

Royalty Pharma Plc (NASDAQ: RPRX) shares rose 1.5% in after-hours trading on Monday after the company announced it had ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management ...

Royalty Pharma plc has completed a transaction to monetize remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in cash, resulting in total proceeds of $530 million ...

Royalty Pharma announced Thursday morning that it has acquired an interest in PureTech Health’s royalty in Karuna Therapeutics’ schizophrenia treatment KarXT for up to $500 million. As per the terms ...

Agios Pharmaceuticals will sell its rights to the 15% royalty it holds on potential U.S. net sales of vorasidenib to Royalty Pharma. Royalty Pharma announced this week that it will pay Agios $905 ...

Royalty Pharma announces $0.22 dividend per share for Q2 2025, payable on June 10 to shareholders of record by May 16. Royalty Pharma plc has announced that its board of directors has approved a ...

Investing.com -- Royalty Pharma Plc (NASDAQ:RPRX) stock gained 1.5% in after-hours trading Monday following the company’s announcement that it has acquired the final portion of PTC Therapeutics ’ ...